ClinicalTrials.gg
Sign In
Active, not recruitingNCT03182491ANAMEKUpdated Oct 21, 2026

Mechanisms of Anaphylaxis

An observational study in Anaphylaxis, Allergy and Transfusion Reaction, sponsored by Haukeland University Hospital. Active, not recruiting at 1 site in Norway. Open to participants aged 16 Years to 120 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Haukeland University Hospital · Observational

Updated Oct 21, 2026Primary completion movedStudy completion movedGo to Updates ↓
Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
40
Ages
16 Years to 120 Years
Sex
All
01

Study summary

The purpose of this study is to explore different mechanisms for anaphylaxis and find novel biomarkers for this hypersensitivity syndrome. The study participants are patients with anaphylaxis, patients with mild allergic reactions, and patients with febrile transfusion reactions. The investigators will also include a group of healthy controls.

02

Conditions studied

  • Anaphylaxis
  • Allergy
  • Transfusion Reaction
  • Febrile Transfusion Reaction

Keywords

  • Platelet activating factor
  • Basophil activation test
  • Anaphylatoxins
03

In context

Anaphylaxis

100 studies on the registry are indexed under Anaphylaxis; 20 are open to participants now.

This study's planned enrollment of 40 is below the median of 137 across 48 observational studies indexed under Anaphylaxis.

Browse Anaphylaxis studies →

Lead sponsor

Haukeland University Hospital is the lead sponsor of 284 studies on the registry; 59 are open to participants now.

Browse Haukeland University Hospital studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years to 120 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Adults

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

According to the specific cohort:

  1. Diagnosis of anaphylaxis
  2. Mild allergic reaction
  3. Febrile transfusion reaction
  4. Healthy, no known allergic disease

Exclusion criteria

Exclusion Criteria:

Suspicion or diagnosed sepsis Children

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
40 participants (estimated)
Target follow-up
2 Days
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Anaphylaxis

    Diagnostic Test: Biomarkers (platelet activating factor [PAF], anaphylatoxins) and basophil activation test (BAT)

  • Febrile transfusion reactions

    Diagnostic Test: Biomarkers (platelet activating factor [PAF], anaphylatoxins) and basophil activation test (BAT)

  • Mild allergic reactions

    Diagnostic Test: Biomarkers (platelet activating factor [PAF], anaphylatoxins) and basophil activation test (BAT)

  • Healthy controls

    Diagnostic Test: Biomarkers (platelet activating factor [PAF], anaphylatoxins) and basophil activation test (BAT)

Interventions

  • Diagnostic testBiomarkers (platelet activating factor [PAF], anaphylatoxins) and basophil activation test (BAT)

    Analysis of biomarkers and basophil activation test

06

What researchers measure

Primary outcomes

  1. Clarify mechanisms for anaphylaxis and establish biomarkers for this syndrome

    Immunological/nonimmunological mechanism

    Time frame: 2 days

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Apr 2017 (actual). Primary completion is estimated for Dec 2028, 140 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: primary completion Oct 2026 → Dec 2028 and completion Oct 2026 → Dec 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2017
First posted
Jun 9, 2017
StartActual
Apr 28, 2017
Primary completionEst.
Dec 31, 2028was Oct 2026
CompletionEst.
Dec 31, 2028was Oct 2026
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 1, 2026→Dec 31, 2028
Oct 21, 2026
Study completion
Oct 1, 2026→Dec 31, 2028
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Primary completion Oct 1, 2026→Dec 31, 2028
    Study completion Oct 1, 2026→Dec 31, 2028
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT03182491
Lead sponsor
Haukeland University Hospital
Responsible party
Sponsor
First posted
Jun 9, 2017
Start date
Apr 28, 2017
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Oct 21, 2026

Study contacts

Torunn O Apelseth, MD, PhD
study director · Haukeland University Hospital
Morten Y Isaksen, MD
principal investigator · Haukeland University Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Anaphylaxis →

Other studies from this sponsor

Haukeland University Hospital →

Start the discussion